STZ is normally used to induce diabetes in pancreatic rats by DNA alkylation and β cell fragmentation.18 STZ selectively devastates the β cells, which secrete insulin, decreasing the β cell efficiency and resulting in diabetes mellitus.19 Many living β cells remain after treatment with low-dose STZ, and their regeneration is also possible.18 The gene discussed is INS; the disease is diabetes mellitus.